CYCLERION THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-1
Book Value Per Share
$3
Free Cash Flow Per Share
$-1
Cash Per Share
$1
Revenue Per Share
$1
OCF Per Share
$-1
Return on Equity
-39.3%
Return on Assets
-36.1%
Return on Invested Capital
-43.8%
Current Ratio
5.15
Quick Ratio
5.15
Asset Turnover
0.21
Days Sales Outstanding
175.99
R&D / Revenue
46.2%
SBC / Revenue
21.3%
Capex / Revenue
—
Working Capital
$4M
Net Current Asset Value
$5M
Invested Capital
$9M
OCF / Net Income
0.94
FCF / Net Income
0.94
Accruals Ratio (Sloan)
-2.1%
Net Debt
$-3M
Net Debt / EBITDA
0.65
Capex Coverage
—
Tangible Common Equity
$9M
TCE / Total Assets
91.0%
NOPAT
$-4M
Cash ROIC
-37.0%
WC / Revenue
180.1%
Capex / D&A
—
Reinvestment Rate
—
Asset Growth vs Revenue Growth
0.6%
Revenue 5Y CAGR
-2.0%
Book Value 5Y CAGR
-31.3%
Stock Price (FY-end)
$1
Market Cap
$4M
P/S Ratio
1.95
P/B Ratio
0.44
P/TB Ratio
0.44
Enterprise Value
$800K
EV / Sales
0.39
FCF Yield
-82.0%
Shareholder Yield
-10.9%
R&D Yield
23.7%
Capex Yield
—
Shares Variation (YoY)
26.3%
Beta (5Y)
1.01
Cost of Equity
9.5%
52W High
$5
52W Low
$1
Trailing Return 1Y
-61.5%
Trailing Return 5Y
-98.0%
F-Score (Piotroski)
1.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.